Advertisement

Immunodiagnosis of Lymphoid and Mononuclear Phagocytic Neoplasms

  • E. S. Jaffe
  • J. Cossman
Part of the Developments in Oncology book series (DION, volume 34)

Abstract

The malignant lymphomas represent multiple diseases with diverse morphologic and clinical expressions. Morphologic classification schemes have been shown to be useful in delineating natural history, prognosis and response to therapy (1). However, in some instances distinctive morphologic entities may be very closely related clinically and/or biologically, whereas other diseases that share morphologic similarities may be clinically and biologically quite distinct. The application of modern immunologic techniques and concepts has permitted the development of a conceptual framework which may be used to decipher the morphologic diversity of these neoplasms, and has shown the relationship of lymphoid and mononuclear phagocytic neoplasms to the normal immune system (2).

Keywords

Follicular Lymphoma Lymphoblastic Lymphoma Histiocytic Sarcoma Small Lymphocytic Lymphoma Malignant Histiocytosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rosenberg SA, Berard CW, Brown BW, Burke J, Dorfman RF, Glatstein E, Hoppe RT, Simon RT: National Cancer Institute sponsored study of classification of non-Hodgkin’s lymphomas: summary and description of a Working Formulation for clinical usage. Cancer(49).2112–2135, 1982.CrossRefGoogle Scholar
  2. 2.
    Mann RB, Jaffe ES, Berard CW: Malignant lymphomas: a conceptual understanding of morphological diversity. Am J Pathol(94):105–192, 1979.PubMedGoogle Scholar
  3. 3.
    Jaffe ES, Braylan RC, Frank MM, Green I, Berard CW: Heterogeneity of immunologic markers and surface morphology in “childhood lymphoblastic lymphoma.” Blood(44):930, 1974.Google Scholar
  4. 4.
    Bollum FJ: Terminal deoxynucleotidyl transferase as a hematopoietic cell marker. A review. Blood(54):1203–1215, 1979.Google Scholar
  5. 5.
    Shibata A, Bennett JM, Castoldi GL, Catovsky D, Flandrin G, Jaffe ES, Katayama I, Nanba K, Schmalz I, F Yam LT: International Committee for Standardization in Hematology (ICSH). Recommended methods for cytochemical procedures in hematology. Clin Lab Haematol, in press.Google Scholar
  6. 6.
    Nanba J, Jaffe ES, Braylan RC, Soban EJ, Berard CW: Alkaline phosphatase positive malignant lymphomas. A subtype of B-cell lymphomas. Am J Clin Pathol(68):535–542, 1977.PubMedGoogle Scholar
  7. 7.
    Bowling MC: Histopathology Laboratory Procedures of the Pathologic Anatomy Branch of the National Cancer Institute. U.S. Govt. Printing Office, Washington, D.C., 1967.Google Scholar
  8. 8.
    Korsmeyer SJ, Hieter PA, Ravetch JV, Poplack DG, Waldmann TA, Leder P: Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B cells. Proc Natl Acad Sci USA(78): 7096–7100, 1981.PubMedCrossRefGoogle Scholar
  9. 9.
    Cossman J, Neckers L, Arnold A, Korsmeyer S: Induction of differentiation in a case of common acute lymphoblastic leukemia. N Engl J Med(307):1251–1254, 1982.PubMedCrossRefGoogle Scholar
  10. 10.
    Vogler LB, Crist W, Bockman DE, Pearl ER, Lawton AR, Cooper MD: Pre-B-cell leukemia. A new phenotype of childhood lymphoblastic leukemia. N Engl J Med(298):872–878, 1978.PubMedCrossRefGoogle Scholar
  11. 11.
    Greaves MF, Janossy G, Roberts M, Rapson NT, Ellis RB, Chessels J, Lister TA, Catovsky D: Membrane phenotyping: diagnosis, monitoring and classification of acute “lymphoid” leukemias. In: Thierfeler S, Rodt H, Thiel, E (eds) Immunological Diagnoses of Leukemias and Lymphomas. Springer Verlag, New York, 1977, pp. 61–75.CrossRefGoogle Scholar
  12. 12.
    Ritz J, Pesondo JM, Notis-McConarty J, Lazarus H, Schlossman SF: A monoclonal antibody to human acute lymphoblastic leukemia antigen. Nature(283): 583, 1980.PubMedCrossRefGoogle Scholar
  13. 13.
    Korsmeyer SJ, Arnold A, Bakhshi A, Ravetch JV, Siebenlist U, Hieter PA, Sharrow SO, Le Bien TW, Kersey JH, Poplack DG, Leder P, Waldmann TA: Immunoglobulin gene rearrangements and cell surface antigen expression in acute lymphocytic leukemias of T-cell and B-cell precursor origins. J Clin Invest(71).301–313, 1983.PubMedCrossRefGoogle Scholar
  14. 14.
    Cossman J, Chused T, Fisher R, Magrath I, Bollum FJ, Jaffe ES: Diversity of immunologic phenotypes of lymphoblastic lymphoma. Cancer Res(43):4486–4490, 1983.PubMedGoogle Scholar
  15. 15.
    Miller RA, Maloney DG, Levy R, Warnke R: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med(306): 517–522, 1982.PubMedCrossRefGoogle Scholar
  16. 16.
    Arnold A, Cossman J, Bakhshi A, Jaffe ES, Waldmann TA, Korsmeyer SJ: Immunoglobulin gene rearrangements as unique clonal markers in human lymphoid neoplasms. N Engl J Med (309):1593–1599, 1983.PubMedCrossRefGoogle Scholar
  17. 17.
    Cossman J, Neckers LM, Hsu SM, Longo D, Jaffe ES: Low grade lymphomas: Expression of developmentally regulated B-cell antigens. Am J Pathol(114):117–124, 1984.Google Scholar
  18. 18.
    Cossman J, Jaffe ES: Distribution of complement receptor subtypes in non-Hodgkin*s lymphomas of B-cell origin. Blood(58):20–26, 1981.PubMedGoogle Scholar
  19. 19.
    Royston I, Majda JA, Baird SM, Meserve BL, Griffiths JC: Human T-cell antigens defined by monoclonal antigens: The 65,000 dalton antigen of T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin. J Immunol(125) :725–731, 1980.PubMedGoogle Scholar
  20. 20.
    Fu SM, Chiorazzi N, Kunkel HG, Halper JP, Harris SR: Induction of in vitro differentiation and immunoglobulin synthesis of human leukemic B lymphocytes. J Exp Med(148): 1570–1578, 1978.PubMedCrossRefGoogle Scholar
  21. 21.
    Cossman J, Neckers LM, Braziel RM, Trepei JB, Korsmeyer SJ, Bakhshi A: In vitro enhancement of immunoglobulin gene expression in chronic lymphocytic leukemia. J Clin Invest(73):587–592, 1984.PubMedCrossRefGoogle Scholar
  22. 22.
    Jaffe ES, Braylan RC, Nanba K, Frank MM, Berard CW: Functional markers: A new perspective on malignant lymphomas. Cancer Treat Rep(61):953–962, 1977.PubMedGoogle Scholar
  23. 23.
    Swerdlow SH, Habeshaw JA, Murray LJ, Dhaliwal HS, Lister TA, Stansfield AG: Centrocytic lymphoma: A distinct clinicopathologic and immunologic entity. Am J Pathol (113).181–197, 1983.PubMedGoogle Scholar
  24. 24.
    Jaffe ES, Shevach EM, Frank MM, Berard DW, Green I: Nodular lymphoma: Evidence for origin from follicular B lymphocytes. N Engl J Med(290):813, 1974.PubMedCrossRefGoogle Scholar
  25. 25.
    Braziel RM, Neckers LM, Jaffe ES, Cossman J: Induction of immunoglobulin secretion in follicular non-Hodgkin’s lymphomas: Role of immunoregulatory T cells. Blood, in press.Google Scholar
  26. 26.
    Jaffe ES, Strauchen JA, Berard CW: Predictability of immunologic phenotype by morphologic criteria in diffuse aggressive non-Hodgkin’s lymphomas. Am J Clin Pathol(77): 46–49, 1982.PubMedGoogle Scholar
  27. 27.
    Mann RB, Jaffe ES, Braylan RC, Nanba K, Frank MM, Ziegler JL, Berard CW: Non-endemic Burkitt’s lymphoma. A B-cell tumor related to germinal centers. N Engl J Med(295):685–691, 1976.PubMedCrossRefGoogle Scholar
  28. 28.
    Jaffe ES, Smith SA, Magrath IT, Freeman CB, Alabaster 0: Induction of complement receptors in human cell lines derived from undifferentiated lymphomas. Lab Invest (45):295–301, 1981.PubMedGoogle Scholar
  29. 29.
    Ritz J, Nadler LM, Bhan AK, Notis-McConarty J, Pesando JM, Schlossman SF: Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B- and T-cell lineage. Blood(58):648–652, 1981.PubMedGoogle Scholar
  30. 30.
    Braziel RM, Keneklis T, Donion JA, Hsu SM, Cossman J, Bollum FJ, Jaffe ES: Terminal deoxynucleotidyl transferase in non-Hodgkin* s lymphoma. Am J Clin Pathol(80) :655–659, 1983.PubMedGoogle Scholar
  31. 31.
    Croce CM, Tsujimoto Y, Erikson J, Nowell PC: Chromosomal translocation and B-cell neoplasia. Lab Invest(51):258–267, 1984.PubMedGoogle Scholar
  32. 32.
    Braylan RC, Jaffe ES, Triche JJ, Nanba K, Fowkles BJ, Metzger H, Frank MM, Do Ian MS, Yee CL, Green I, Berard CW: Structural and functional properties of the “hairy” cells of leukemic reticuloendotheliosis. Cancer(41): 210–227, 1978.PubMedCrossRefGoogle Scholar
  33. 33.
    Cohen HJ, George ER, Kremer WB: Hairy cell leukemia: Cellular characteristics including surface immunoglobulin dynamics and biosynthesis. Blood(53): 764, 1979.PubMedGoogle Scholar
  34. 34.
    Korsmeyer S, Greene W, Cossman J, Hsu SM, Neckers L, Marshall S, Jensen J, Bakhshi A, Leonard W, Jaffe ES, Waldmann T: Rearrangement and expression of immunoglobulin genes and expression of TAC antigen in hairy cell leukemia. Proc Natl Acad Sci USA(80):4522–4526, 1983.PubMedCrossRefGoogle Scholar
  35. 35.
    Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM: Expression of human B-cell-associated antigens on leukemias and lymphomas: A model of human B-cell differentiation. Blood(63):1425–1433, 1984.Google Scholar
  36. 36.
    Bernard A, Boumsell L, Reinherz EL, Nadler LM, Ritz J, Coppin H, Richard Y, Valensi F, Dausset J, Flandrin G, Lemerle J, Schlossman SF: Cell surface characterization of malignant T cells from lymphoblastic lymphoma using monoclonal antibodies: Evidence for phenotypic differences between malignant T cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood(57): 1105–1110, 1981.PubMedGoogle Scholar
  37. 37.
    Brouet JC, Flandrin G, Sasportes M, Preud’homme JL, Seligmann M: Chronic lymphocytic leukemia of T-cell origin. Lancet(ii)890–893, 1975.CrossRefGoogle Scholar
  38. 38.
    Pandolfi F, Strong DM, Slease RB, Smith ML, Ortaldo JR, Herberman RB: Characterization of a suppressor T-cell chronic lymphocytic leukemia with ADCC but not NK activity. Blood(56).653–660, 1980.PubMedGoogle Scholar
  39. 39.
    Hooks JJ, Haynes BF, Detrick-Hooks D, Diehl LF, Gerrard TL, Fauci AS: Gamma (immune) interferon production by leukocytes from a patient with Tγ -cell proliferative disease. Blood(59):198–201, 1982.PubMedGoogle Scholar
  40. 40.
    Aisenberg AC, Wilkes BM, Harris NL, Ault KA, Carey RW: Chronic T-cell lymphocytosis with neutropenia: Report of a case studied with monoclonal antibodies. Blood(58): 818–822, 1981.PubMedGoogle Scholar
  41. 41.
    Broder S, Bunn PA Jr: Cutaneous T-cell lymphomas. Semin Oncol(7):310–331, 1980.PubMedGoogle Scholar
  42. 42.
    Broder S, Waldmann TA: Helper activity by lymphocytes derived from patients with the Sezary syndrome. J Clin Invest(58).1297–1306, 1976.PubMedCrossRefGoogle Scholar
  43. 43.
    Jaffe ES: Pathologic and clinical spectrum of post-thymic T-cell malignancies. Special article. Cancer Investigation 2(5), 1984.CrossRefGoogle Scholar
  44. 44.
    Cossman J, Jaffe ES, Fisher RI: Immunologic phenotypes of diffuse aggressive non-Hodgkin’s lymphomas: Correlation with clinical features. Cancer(54):1310–1317, 1984.PubMedCrossRefGoogle Scholar
  45. 45.
    Jaffe ES, Blattner WA, Blayney DW, Bunn PA Jr, Cossman J, Robert-Guroff M, Gallo RC: The pathologic spectrum of HTLV-associated leukemia lymphoma in the United States. Am J Surg Pathol(8): 263–275, 1984.PubMedCrossRefGoogle Scholar
  46. 46.
    Blayney D, Jaffe E, Blattner W, Cossman J, Robert-Guroff M, Longo D, Bunn P, Gallo R: The human T-cell leukemia/ lymphoma virus (HTLV) associated with American adult T-cell leukemia/lymphoma (ATL). Blood(62):401–405, 1983.PubMedGoogle Scholar
  47. 47.
    Jaffe ES, Costa J, Fauci AS, Cossman J, Tsokos M: Malignant lymphoma and erythrophagocytosis simulating malignant histiocytosis. Am J Med(75): 741–749, 1983.PubMedCrossRefGoogle Scholar
  48. 48.
    Simrell CR, Crabtree GR, Cossman J, Fauci AS, Jaffe ES: Stimulation of phagocytosis by a T-cell-lymphoma-derived lymphokine. JEn: Vitetta E (ed) B- and T-Cell Tumors. UCLA Symposia in Molecular and Cellular Biology. Vol 24. Academic Press, New York, 1982, pp. 247–252.Google Scholar
  49. 49.
    Jaffe ES, Shevach EM, Sussman EH, Frank MM, Green I, Berard CW: Membrane receptor sites for the identification of lymphoreticular cells in benign and malignant conditions. Br J Cancer(31(Suppl II))107–120, 1975.Google Scholar
  50. 50.
    Risdall RJ, McKenna RW, Nesbit ME, Krivit W, Balfour HH, Simmons RL, Brunning RD: Virus-associated hemophagocytic syndrome, a benign histiocytic proliferation distinct from malignant histiocytosis. Cancer(44):993–1002, 1979.PubMedCrossRefGoogle Scholar
  51. 51.
    Van der Valk P, Meijer CJLM, Willemze R, Oosterom AT, Spaander PJ, Te Velde J: Histiocytic sarcoma (true histiocytic lymphoma) a clinico-pathological study of 20 cases. Histopathology(8):105–123, 1984.PubMedCrossRefGoogle Scholar
  52. 52.
    Breard J, Reinherz EL, Kung PC, Goldstein G, Schlossman SF: A monoclonal antibody reactive with human blood monocytes. J Immunol(124): 1943–1948, 1980.PubMedGoogle Scholar
  53. 53.
    Hsu SM, Jaffe ES: Leu Ml and peanut agglutinin stain the neoplastic cells of Hodgkin’s disease. Am J Clin Pathol (82):29–32 1984.PubMedGoogle Scholar
  54. 54.
    Isaacson P, Wright DH, Jones DB: Malignant lymphoma of true histiocytic (monocyte/macrophage) origin. Cancer (51):80–91, 1983.PubMedCrossRefGoogle Scholar
  55. 55.
    Young RC, Corder MA, Haynes HA, DeVita VT: Delayed hypersensitivity in Hodgkin’s disease. A study of 103 cases. Am J Med(52):63–72, 1973.CrossRefGoogle Scholar
  56. 56.
    Levy R, Kaplan HS: Impaired lymphocyte function in untreated Hodgkin’s disease. N Engl J Med(290): 181–186, 1974.PubMedCrossRefGoogle Scholar
  57. 57.
    Fuks Z, Strober S, Kaplan HS: Interaction between serum factors and T lymphocytes in Hodgkin* s disease. N Engl J Med(295):1273–1278, 1976.PubMedCrossRefGoogle Scholar
  58. 58.
    Garvin AJ, Spicer SS, Parmley RT, Munster AM: Immunohisto-chemical demonstration of IgG in Reed-Sternberg and other cells in Hodgkin’s disease. J Exp Med(139):1077–1083, 1974.PubMedCrossRefGoogle Scholar
  59. 59.
    Cossman J, Deegan MJ, Schnitzer B: Complement receptor B lymphocytes in nodular sclerosing Hodgkin’s disease. Cancer(39):2166–2174, 1977.PubMedCrossRefGoogle Scholar
  60. 60.
    Kadin ME, Stites DP, Levy R, Warnke R: Exogenous immunoglobulin and the macrophage origin of Reed-Sternberg cells in Hodgkin’s disease. N Engl J Med(299):1208, 1978.PubMedCrossRefGoogle Scholar
  61. 61.
    Kadin ME: Possible origin of the Reed-Sternberg cell from an interdigitating reticulum cell. Cancer Treat Rep(66): 601–608, 1982.PubMedGoogle Scholar
  62. 62.
    Longmire RL, McMillan R, Yelenosky R, Armstrong S, Lang JE, Craddock CG: In vitro splenic IgG synthesis in Hodgkin’s disease. N Engl J Med(289): 763–767, 1973.PubMedCrossRefGoogle Scholar
  63. 63.
    DeVita VT: Lymphocyte reactivity in Hodgkin’s disease: A lymphocyte civil war. N Engl J Med(289):801–802, 1973.PubMedCrossRefGoogle Scholar
  64. 64.
    Diehl V, Kirschner HH, Burrighter H, Stein H, Fonatsch C, Gerdes J, Schaadt M, Heit W, Uchanska-Ziegler B, Ziegler A, Heintz F, Sueno K: Characteristics of Hodgkin’s-disease-derived cell lines. Cancer Treat Rep(66):615–632, 1982.PubMedGoogle Scholar
  65. 65.
    Stein H, Gerdes J, Schwab U, Lemke H, Mason DY, Ziegler A, Schienle W, Diehl U: Identification of Hodgkin and Sternberg-Reed Sternberg cells as a unique cell type derived from a newly detected small cell population. Int J Cancer(30):445–459, 1982.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1985

Authors and Affiliations

  • E. S. Jaffe
  • J. Cossman

There are no affiliations available

Personalised recommendations